Cara Therapeutics, Inc. (CARA)
NASDAQ: CARA · Real-Time Price · USD
0.307
+0.002 (0.59%)
Nov 21, 2024, 1:44 PM EST - Market open
Cara Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 5.12 | 20.27 | 41.87 | 23.03 | 135.08 | 19.89 | Upgrade
|
| Other Revenue | 3.57 | 0.7 | - | - | - | - | Upgrade
|
| Revenue | 8.69 | 20.97 | 41.87 | 23.03 | 135.08 | 19.89 | Upgrade
|
| Revenue Growth (YoY) | -59.08% | -49.92% | 81.81% | -82.95% | 579.28% | 47.64% | Upgrade
|
| Cost of Revenue | 31.58 | 113.55 | 98.01 | 81.56 | 107.07 | 113.16 | Upgrade
|
| Gross Profit | -22.9 | -92.58 | -56.14 | -58.54 | 28.01 | -93.28 | Upgrade
|
| Selling, General & Admin | 26.86 | 28.92 | 31.39 | 30.55 | 22.63 | 18.4 | Upgrade
|
| Operating Expenses | 59.49 | 28.92 | 31.39 | 30.55 | 22.63 | 18.4 | Upgrade
|
| Operating Income | -82.39 | -121.5 | -87.54 | -89.08 | 5.39 | -111.68 | Upgrade
|
| Interest Expense | -6.46 | -0.6 | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 2.94 | 3.19 | 2.33 | 1.39 | 2.22 | 3.11 | Upgrade
|
| EBT Excluding Unusual Items | -85.91 | -118.91 | -85.21 | -87.69 | 7.6 | -108.57 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.34 | 0.4 | -0.26 | -0.82 | 0.12 | 1.38 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 0.07 | - | - | Upgrade
|
| Pretax Income | -95.53 | -118.51 | -85.47 | -88.44 | 7.72 | -107.19 | Upgrade
|
| Income Tax Expense | - | - | - | - | -0.69 | -0.82 | Upgrade
|
| Net Income | -95.53 | -118.51 | -85.47 | -88.44 | 8.41 | -106.37 | Upgrade
|
| Net Income to Common | -95.53 | -118.51 | -85.47 | -88.44 | 8.41 | -106.37 | Upgrade
|
| Shares Outstanding (Basic) | 55 | 54 | 54 | 51 | 47 | 43 | Upgrade
|
| Shares Outstanding (Diluted) | 55 | 54 | 54 | 51 | 48 | 43 | Upgrade
|
| Shares Change (YoY) | 1.28% | 0.92% | 5.79% | 5.85% | 12.29% | 18.88% | Upgrade
|
| EPS (Basic) | -1.75 | -2.19 | -1.59 | -1.74 | 0.18 | -2.49 | Upgrade
|
| EPS (Diluted) | -1.75 | -2.19 | -1.59 | -1.74 | 0.18 | -2.49 | Upgrade
|
| Free Cash Flow | -77.34 | -94.45 | -78.77 | -60.13 | -5.84 | -109.24 | Upgrade
|
| Free Cash Flow Per Share | -1.41 | -1.74 | -1.47 | -1.19 | -0.12 | -2.56 | Upgrade
|
| Gross Margin | -263.62% | - | -134.09% | -254.19% | 20.74% | - | Upgrade
|
| Operating Margin | -948.50% | -579.43% | -209.08% | -386.85% | 3.99% | -561.60% | Upgrade
|
| Profit Margin | -1099.76% | -565.21% | -204.16% | -384.06% | 6.23% | -534.91% | Upgrade
|
| Free Cash Flow Margin | -890.42% | -450.46% | -188.15% | -261.10% | -4.32% | -549.35% | Upgrade
|
| EBITDA | -82.11 | -121.24 | -87.29 | -88.84 | 5.59 | -111.48 | Upgrade
|
| EBITDA Margin | - | - | -208.49% | - | 4.14% | - | Upgrade
|
| D&A For EBITDA | 0.27 | 0.26 | 0.25 | 0.25 | 0.21 | 0.2 | Upgrade
|
| EBIT | -82.39 | -121.5 | -87.54 | -89.08 | 5.39 | -111.68 | Upgrade
|
| EBIT Margin | - | - | -209.08% | - | 3.99% | - | Upgrade
|
| Revenue as Reported | 8.69 | 20.97 | 41.87 | 23.03 | 135.08 | 19.89 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.